MED Medifast, Inc.
Medifast, Inc., through its subsidiaries, operates as a health and wellness company that provides habit-based and coach-guided lifestyle solutions for weight loss in the United States. The company offers weight loss, weight management, and healthy living products comprising bars, cereals, snack straws, hot chocolate, hearty choices, oatmeal, pancakes, puddings, soft serves, shakes, smoothies, soft bakes, soups, amino acid blends, whey protein, hot beverages, brownies, and mini meals under the Essential Fuelings, OPTAVIA ASCEND, and OPTAVIA ACTIVE categories, as well as daily nutrient packs, including multivitamins, minerals, and omega-3 fatty acid supplements. It also provides lifestyle plans, which provides a targeted reset of the body's metabolism by activating strong and targeted fat burn; Optimal Weight 4 & 2 & 1 Plan and Optimal Weight 4 & 2 ACTIVE Plan, which is designed for clients who want to continue eating all food groups or want a flexible meal plan to achieve a healthy weight; OPTAVIA Optimization Plan, a personalized approach to help clients' long-term weight management; and OPTAVIA GLP-1 Nutrition Support Plan, a nutritional companion to GLP-1 medication that allows clients to focus on weight loss. In addition, the company offers metabolic synchronization, a science that reverses metabolic dysfunction through a targeted reset of the body's metabolism. It markets its products through point-of-sale transactions executed over an e-commerce platform. The company serves health and wellness consumers. The company was formerly known as Healthrite, Inc. and changed its name to Medifast, Inc. in May 2001. Medifast, Inc. was incorporated in 1980 and is headquartered in Baltimore, Maryland.…
Industry Peers
Personal ServicesKey Statistics
About Medifast (NYSE: MED)
›
Medifast (NYSE: MED) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Personal Services industry, part of the Consumer Cyclical sector, and reports about 380 employees.
The shares were at 11.98 USD on 19 November 2026, up 5.3% over 52 weeks. Its 52-week range is 9.220 USD to 13.63 USD: the price is 12.1% below the high and 29.9% above the low.
Its market capitalisation is 133.97M USD.
Medifast reports return on equity of -9.4%, an operating margin of -11.6% and revenue down 19.4% year over year.
It holds more cash than debt, a net cash position of 151.85M USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. One analyst covers the stock; their mean price target of 12.00 USD is 0.2% above the current price. The next earnings report is expected on 18 February 2027.